---
title: "Human Normal Immunoglobulin and Anti-D Immunoglobulin (CMU Call Off)"
ocid: "ocds-r6ebe6-0000660005"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000660005"
markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000660005.md"
json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000660005.json"
source: "Public Contracts Scotland"
current_stage: "Award"
buyer: "THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (\"NSS\")"
published: "2021-08-23"
---

# Human Normal Immunoglobulin and Anti-D Immunoglobulin (CMU Call Off)

Buyer: THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("NSS")  
Current stage: Award  
OCID: ocds-r6ebe6-0000660005

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000660005)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000660005.json)

## Summary

The Common Services Agency, commonly known as NHS National Services Scotland (NSS), has successfully completed a public procurement process for a National Framework Agreement concerning the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. This agreement commenced on 1 July 2021, with a duration of 18 months and the potential for extensions totalling up to 48 months. The procurement, categorised under the health industry, was conducted through an open procedure, with contract awards completed in June 2021. The procurement activities were largely centred in Edinburgh, UK.

This tender presents significant opportunities for businesses involved in biotechnology and pharmaceuticals, particularly those supplying immunoglobulin products. Companies of various scales, including large suppliers and SMEs, are poised to benefit, especially those capable of delivering products to the Scottish National Blood Transfusion Service in Edinburgh. The comprehensive nature of this framework and the option for multiple awards suggest an ongoing demand for innovative solutions in the healthcare sector, inviting competitive bids for both existing and new business lines.

## Notice

National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months.

### Lot Information

10% Intravenous Immunoglobulin (10% IVIg) - Existing Business

Supply of Human Normal Intravenous Immunoglobulin 10 %, across various vial sizes.

Subcutaneous Immunoglobulin (SCIg) - Existing Business

Supply of Human Normal Intravenous Immunoglobulin for subcutaneous use across various vial sizes

Facilitated Subcutaneous Immunoglobulin (fSCIg) - Existing Business

Supply of Subcutaneous Immunoglobulin with Hyaluronidase (Facilitated Subcutaneous Immunoglobulin)

10% Intravenous Immunoglobulin (10% IVIg) - New Business

Supply of Human Normal Intravenous Immunoglobulin 10 %, across various vial sizes for new patients.

Subcutaneous Immunoglobulin (SCIg) - New Business

Supply of Human Normal Intravenous Immunoglobulin for subcutaneous use across various vial sizes for new patients.

Facilitated Subcutaneous Immunoglobulin (fSCIg) - New Business

Supply of Subcutaneous Immunoglobulin with Hyaluronidase (Facilitated Subcutaneous Immunoglobulin) for new patients.

Anti-D Immunoglobulin (Anti-D)

Supply of Anti-D Immunoglobulin

5% Intravenous Immunoglobulin (5% IVIg) - Existing Business

Supply of Human Normal Intravenous Immunoglobulin 5 %, across various vial sizes.

5% Intravenous Immunoglobulin (5% IVIg) - New Business

Supply of Human Normal Intravenous Immunoglobulin 5 %, across various vial sizes for new patients.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Public Contracts Scotland |
| Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG425046 |
| Notice type | PCS Notice - Website Contract Award Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 23 Aug 2021 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 23 Jun 2021 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Not specified |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("NSS") |
| Locality | EDINBURGH |
| Post town | Edinburgh |
| Postcode | EH12 9EB |
| Country | Scotland |
| ITL 1 | TLM Scotland |
| ITL 2 | TLM1 East Central Scotland |
| ITL 3 | TLM13 City of Edinburgh |
| Local authority | City of Edinburgh |
| Electoral ward | Drum Brae/Gyle |
| Westminster constituency | Edinburgh South West |
| Delivery location | TLM Scotland |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 7 |
| Supplier names | BIO PRODUCTS LABORATORY; BIOTEST (UK; CSL BEHRING; GRIFOLS; LFB BIOPHARMACEUTICALS; OCTAPHARMA; TAKEDA |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33651520 - Immunoglobulins

## Release History

- 23 Aug 2021 at 00:00 - Award - PCS Notice - Website Contract Award Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG425046

## Documents

- https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=AUG425046
  Human Normal Immunoglobulin and Anti-D Immunoglobulin (CMU Call Off) - National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months.

## Notice URLs

- http://
- http://www.nss.nhs.scot/browse/procurement-and-logistics
- https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000660005

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000660005. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000660005.json.